The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, Goeldner RG, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty K (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: WILEY
City/Town: HOBOKEN
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
Mayo Clinic
United States (USA) (US)
Newcastle University
United Kingdom (GB)
Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet
Norway (NO)
Scleroderma Research Consultants LLC
United States (USA) (US)
University Health Network (UHN)
Canada (CA)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Boehringer Ingelheim Pharma GmbH & Co. KG
Germany (DE)
University of Michigan
United States (USA) (US)
United States (USA) (US)
Newcastle University
United Kingdom (GB)
Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet
Norway (NO)
Scleroderma Research Consultants LLC
United States (USA) (US)
University Health Network (UHN)
Canada (CA)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Boehringer Ingelheim Pharma GmbH & Co. KG
Germany (DE)
University of Michigan
United States (USA) (US)
How to cite
APA:
Matteson, E., Kelly, C., Distler, J., Mann-Vold, A.M.H., Seibold, J., Mittoo, S.,... Flaherty, K. (2019). The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.
MLA:
Matteson, Eric, et al. "The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2019.
BibTeX: Download